Feed on
Posts
Comments

Australia’s adult stem cell company, Mesoblast Limited has announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company,
Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or ‘off-the-shelf’, adult stem cells for patients with heart attacks.
The [...]

Share and Enjoy:
  • Print
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks

Trackback URI | Comments RSS

Leave a Reply

General Health
Health Care
Nutrition
Personal Care
Sex and Sensuality
Bestsellers